Objectives: To compare costs and clinical benefits of three additional therapies to metformin (MF) for patients with diabetes mellitus type 2 (DM2). Methods: A discrete event simulation model was built to estimate the cost-utility ratio (cost per quality-adjusted life years [QALY]) of saxagliptine as an additional therapy to MF when compared to rosiglitazone or pioglitazone. A budget impact model (BIM) was built to simulate the economic impact of saxagliptine use in the context of the Brazilian private health system. Results: The acquiring medication costs for the hypothetical patient group analyzed in a time frame of three years were R$10,850,185, R$14,836,265 and R$ 14,679,099 for saxagliptine, pioglitazone and rosiglitazone, respectively. Saxagliptine showed lower costs and greater effectiveness in both comparisons, with projected savings for the first three years of R$ 3,874 and R$3,996, respectively. The BIM estimated cumulative savings of R$417,958 with the repayment of saxagliptine in three years from the perspective of a health plan with 1,000,000 covered individuals. Conclusion: From the perspective of private paying source, the projection is that adding saxagliptine with MF save costs when compared with the addition of rosiglitazone or pioglitazone in patients with DM2 that have not reached the HbA1c goal with metformin monotherapy. The BIM of including saxagliptine in the reimbursement lists of health plans indicated significant savings on the three-year horizon. © 2012 Elsevier Editora Ltda. All right reserved.583294301King, H., Aubert, R.E., Herman, W.H., Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections (1998) Diabetes Care, 21 (9), pp. 1414-1431Barceló, A., Rajpathak, S., Incidence and prevalence of diabetes mellitus in the Americas (2001) Rev Panam Salud Pública, 10 (5), pp. 300-308Yach, D., Stuckler, D., Brownell, K.D., Epidemiologic and economic consequences of the global epidemics of obesity and diabetes (2006) Nat Med, 12 (1), pp. 62-66Bosi, P.L., Carvalho, A.M., Contrera, D., Casale, G., Pereira, M.A., Gronner, M.F., Prevalência de diabetes melito e tolerância à glicose diminuída na população urbana de 30 a 79 anos da cidade de São Carlos, São Paulo (2009) Arq Bras Endocrinol Metab, 53 (6), pp. 726-732Costa, J.S.D., Olinto, M.T.A., Assunção, M.C.F., Gigante, D.P., McEdo, S., Menezes, A.M.B., Prevalence of diabetes mellitus in southern Brazil: A population-based study (2006) Rev Saúde Pública, 40 (3), pp. 542-545Schaan, B.D.A., Harzheim, E., Gus, I., Cardiac risk profile in diabetes mellitus and impaired fasting glucose (2004) Rev Saúde Pública, 38 (4), pp. 529-536Torquato, M.T.D.C.G., Montenegro Junior, R.M., Viana, L.A.L., Souza, R.A.H.G.D., Lanna, C.M.M., Lucas, J.C.B., Prevalence of diabetes mellitus and impaired glucose tolerance in the urban population aged 30-69 years in Ribeirão Preto (São Paulo), Brazil (2003) São Paulo Med J, 121 (6), pp. 224-230Malerbi, D.A., Franco, L.J., Multicenter study of the prevalence of diabetes mellitus and impaired glucose tolerance in the urban Brazilian population aged 30-69 yr. The Brazilian Cooperative Group on the Study of Diabetes Prevalence (1992) Diabetes Care, 15 (11), pp. 1509-1516Schaan, B.D., Harzheim, E., Gus, I., Cardiac risk profile in diabetes mellitus and impaired fasting glucose (2004) Rev Saúde Pública, 38 (4), pp. 529-536Oliveira, A.F., Valente, J.G., Leite, I.D.C., Shcramm, J.M.D.A., Azevedo, A.S.R., Gadelha, A.M.J., Global burden of disease attributable to diabetes mellitus in Brazil (2009) Cad Saúde Pública, 25 (6), pp. 1234-1244(2002) The World Health Report 2002: Reducing risks, promoting healthy life, , http://www.who.int/whr/2002/en/whr02_en.pdf, World Health Organization. Geneva. Available fromPanarotto, D., Salibe, M., Oliveira, D., Teles, A.R., Controle glicêmico de pacientes diabéticos tipo 2 nos serviços público e privado de Saúde (2009) Arq Bras Endocrinol Metab, 53 (6), pp. 733-740Mendes, A.B.V., Fittipaldi, J.A.S., Neves, R.C.S., Chacra, A.R., Moreira, E.D., Prevalence and correlates of inadequate glycaemic control: Results from a nationwide survey in 6,671 adults with diabetes in Brazil (2010) Acta Diabetologica, 47 (2), pp. 137-145Gomes, M.D.B., Gianella, D., Faria, M., Tambascia, M., Fonseca, R.M., Réa, R., Prevalence of type 2 diabetic patients within the targets of care guidelines in daily clinical practice: A multi-center study in Brazil (2006) Rev Diabet Stud, 3 (2), pp. 73-78Stratton, I.M., Adler, A.I., Neil, H.A., Matthews, D.R., Manley, S.E., Cull, C.A., Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study (2000) BMJ, 321 (7258), pp. 405-412Gerich, J., The importance of tight glycemic control (2005) Am J Med, 118 (SUPPL. 9A), pp. 7S-11SChaves, L., Anselmi, M., Barbeira, C., Hayashida, M., Estudo da sobrevida de pacientes submetidos a hemodiálise e estimativa de gastos no município de Ribeirão Preto-SP (2002) Rev Esc Enferm USP, 36 (2), pp. 193-199Milman, M.H.S.A., Leme, C.B.M., Borelli, D.T., Kater, F.R., Baccili, E.C.D.C., Rocha, R.C.M., Pé diabético: Avaliação da evolução e custo hospitalar de pacientes internados no Conjunto Hospitalar de Sorocaba (2001) Arq Bras Endocrinol Metab, 45 (5), pp. 447-451Rezende, K.F., Nunes, M.A.P., Melo, N.H., Malerbi, D., Chacra, A.R., Ferraz, M., Internações por pé diabético: Comparação entre o custo direto estimado e o desembolso do SUS (2008) Arq Bras Endocrinol Metab, 52 (3), pp. 523-530Rosenstock, J., Aguilar-Salinas, C., Klein, E., Nepal, S., List, J., Chen, R., Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes (2009) Curr Med Res Opin, 25 (10), pp. 2401-2411Rosenstock, J., Sankoh, S., List, J., Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes (2008) Diabetes Obes Metab, 10 (5), pp. 376-386DeFronzo, R.A., Hissa, M.N., Garber, A.J., Luiz Gross, J., Yuyan Duan, R., Ravichandran, S., The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone (2009) Diabetes Care, 32 (9), pp. 1649-1655Jadzinsky, M., Pfützner, A., Paz-Pacheco, E., Xu, Z., Allen, E., Chen, R., Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: A randomized controlled trial (2009) Diabetes Obes Metab, 11 (6), pp. 611-622Nita, M.E., Secoli, S.R., Nobre, M., Ono-Nita, S., Health technology assessment: Research methodology (2009) Arq Gastroenterol, 46 (4), pp. 252-256Nita, M.E., Secoli, S.R., Nobre, M., Ono-Nita, S.K., Campino, A.C.C., Sarti, F.M., (2010) Avaliação de tecnologias em saúde: Evidência clínica, análise econômica e análise de decisão, , Porto Alegre: ArtmedClarke, P.M., Gray, A.M., Briggs, A., Farmer, A.J., Fenn, P., Stevens, R.J., A model to estimate the lifetime health outcomes of patients with type 2 diabetes: The United Kingdom prospective diabetes study (UKPDS) outcomes model (UKPDS no. 68) (2004) Diabetologia, 47 (10), pp. 1747-1759Eliaschewitz, F.G., Bahia, L., Cintra, M., Franco, L., Nita, M.E., Treatment patterns and achievement of therapeutic goals in a cohort of type 2 diabetes mellitus patients treated in the brazilian private health care system (PHCS): Initial reports of DIAPS 79 study (2010) Value Health, 13 (7), pp. A301. , DIAPS 79 Study GroupYki-Järvinen, H., Kauppinen-Mäkelin, R., Tiikkainen, M., Vähätalo, M., Virtamo, H., Nikkilä, K., Insulin glargine or NPH combined with metformin in type 2 diabetes: The LANMET study (2006) Diabetologia, 49 (3), pp. 442-451Polonsky, T., Mazzone, T., Davidson, M., The clinical implications of the CHICAGO study for the management of cardiovascular risk in patients with type 2 diabetes mellitus (2009) Trends Cardiovasc Med, 19 (3), pp. 94-99Tewart, M.W., Cirkel, D.T., Furuseth, K., Donaldson, J., Biswas, N., Starkie, M.G., Effect of metformin plus roziglitazone compared with metformin alone on glycaemic control in well-controlled Type 2 diabetes (2006) Diabet Med, 23 (10), pp. 1069-1078Mwamburi, M., Xu, Y., Fahrbach, K., (2009) A systematic review and meta-analysis of clinical efficacy and safety of mixed treatments for type 2 diabetes Mellitus, , Lexington, MA: United BioSource CorporationPhung, O.J., Scholle, J.M., Talwar, M., Coleman, C., Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes (2010) JAMA, 303 (14), pp. 1410-1418(2010) Health survey for England, , http://www.dh.gov.uk/en/Publicationsandstatistics/PublishedSurvey/HealthSurveyForEngland/Healthsurveyresults/index.htm, Department of Health (England). Department of Health[cited 2011 Nov 22]. Available fromClarke, P., Gray, A., Holman, R., Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62) (2002) Med Decis Making, 22 (4), pp. 340-349Currie, C.J., Morgan, C.L., Poole, C.D., Sharplin, P., Lammert, M., McEwan, P., Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes (2006) Curr Med Res Opin, 22 (8), pp. 1523-1534Belon, A.P., Maria, P., Bergamo, S., Berti, M., Barros, D.A., Luis, C., Diabetes em idosos: Perfil sócio-demográfico e uso de serviços de saúde (2008) XVI Encontro Nacional de Estudos Populacionais, , In: ABEP Caxambu-MG set/out 29-03. Belo Horizonte: ABEP2008Waugh, N., Cummins, E., Royle, P., Clar, C., Marien, M., Richter, B., Newer agents for blood glucose control in type 2 diabetes: Systematic review and economic evaluation (2010) Health Technol Assess, 14 (36), pp. 1-248Newer agents for blood glucose control in type 2 diabetes (2009) NICE Short Clinical Guidance, 87, pp. 1-102. , National Institute for Health and Clinical ExcellenceLi, R., Zhang, P., Barker, L.E., Chowdhury, F.M., Zhang, X., Cost-effectiveness of interventions to prevent and control diabetes mellitus: A systematic review (2010) Diabetes Care, 33 (8), pp. 1872-1894Schwarz, B., Gouveia, M., Chen, J., Nocea, G., Jameson, K., Cook, J., Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy (2008) Diabetes Obes Metab, 10 (SUPPL. 1), pp. 143-155McEwan, P., Evans, M., Bergenheim, K., A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes (2010) Diabetes Obes Metab, 12 (7), pp. 623-630Stettler, C., Allemann, S., Jüni, P., Cull, C.A., Holman, R.R., Egger, M., Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials (2006) Am Heart J, 152 (1), pp. 27-38Adler, A.I., Erqou, S., Lima, T.A., Robinson, A., Association between glycated haemoglobin and the risk of lower extremity amputation in patients with diabetes mellitus-review and meta-analysis (2010) Diabetologia, 53 (5), pp. 840-849